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Polymorphoneuclear leukocytes or neutrophils, a major component of white blood cells,
contribute to the innate immune response in humans. upon sensing changes in the mi-
croenvironment, neutrophils adhere to the vascular wall, migrate through the endothelial
cell (EC†)-pericyte bilayer, and subsequently through the extracellular matrix to reach the
site of inflammation. These cells are capable of destroying microbes, cell debris, and foreign
proteins by oxidative and non-oxidative processes. While primarily mediators of tissue home-
ostasis, there are an increasing number of studies indicating that neutrophil recruitment and
transmigration can also lead to host-tissue injury and subsequently inflammation-related
diseases. Neutrophil-induced tissue injury is highly regulated by the microenvironment of the
infiltrated tissue, which includes cytokines, chemokines, and the provisional extracellular
matrix, remodeled through increased vascular permeability and other cellular infiltrates.
Thus, investigation of the effects of matrix proteins on neutrophil-EC interaction and neu-
trophil transmigration may help identify the proteins that induce pro- or anti-inflammatory
responses. This area of research presents an opportunity to identify therapeutic targets in
inflammation-related diseases. This review will summarize recent literature on the role of
neutrophils and the effects of matrix proteins on neutrophil-EC interactions, with focus on
three different disease models: 1) atherosclerosis, 2) COPD, and 3) tumor growth and pro-
gression. For each disease model, inflammatory molecules released by neutrophils, impor-
tant regulatory matrix proteins, current anti-inflammatory treatments, and the scope for
further research will be summarized.
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Neutrophils: The Good, The Bad, and
The Ugly
The human body is equipped with a
dynamic immune system that can sense
and  respond  appropriately  to  microbial
antigens, foreign material, and tissue in-
jury. The immune system can be broadly
categorized into two responses: 1) the in-
nate immune response, which acts first to
non-specifically attack all foreign bodies
or pathogens and 2) the adaptive immune
response,  which  is  responsible  for  the
pathogen-specific, long-lasting protective
immunity. A primary component of the in-
nate  immune  system  are  the  polymor-
phonuclear neutrophils, which are short
lived cells that act as the first responders
to infection [1]. In case of an acute in-
flammatory  response  to  a  foreign  body
(i.e., bacteria), the neutrophils from the
blood vessels migrate to the site of infec-
tion within minutes [1]. This migration of
neutrophils across the blood vessel into the
extravascular  compartment  is  mediated
through temporally sequenced mechanical,
chemical, and molecular processes known
together as the Leukocyte Adhesion Cas-
cade [2,3]. The process begins with the ini-
tial capture of neutrophils from the free
blood stream to the endothelial cell (EC)
surface, mediated by the interaction of sur-
face  molecules,  known  as  selectins,  on
both cell types. This is followed by neu-
trophil rolling, in which the cell-cell inter-
action leads to integrin up-regulation in
neutrophils. These integrins are neutrophil-
expressed adhesion molecules that bind to
surface adhesion molecules, including in-
tercellular adhesion molecule 1 (ICAM-1)
and  vascular  cell  adhesion  molecule-1
(VCAM-1)  expressed  on  ECs.  Subse-
quently, the neutrophils crawl along the
vascular lumen and through the vessel wall
to  reach  the  extravascular  space  in  a
process known as transmigration [4]. The
last step of the cascade is the migration of
neutrophils through the extracellular ma-
trix (ECM) to reach the source of infec-
tion. Migration through the ECM entails
neutrophil identification of, adhesion to,
and proteolytic destruction of proteins that
comprise the tissue matrix. As a defense
mechanism, these cells undergo oxidative,
non-oxidative,  and  other  intracellular
processes within the matrix in order to de-
stroy foreign objects, microbes, proteins,
and cell debris [5].
While  primarily  mediators  of  tissue
homeostasis, there are an increasing num-
ber of studies indicating that neutrophil re-
cruitment and transmigration can also lead
to host-tissue injury. The innate immunity
system is very sensitive and slight changes
in the microenvironment can trigger neu-
trophil recruitment and response [5]. Neu-
trophil-induced  tissue  injury  is  highly
regulated by the infiltrated tissue, which in-
cludes cytokine, chemokines, and the pro-
visional ECM, remodeled through increased
vascular permeability and other cellular in-
filtrates. The major components of the mi-
croenvironment that influence neutrophil
recruitment and response at the site of in-
flammation can be categorized into the fol-
lowing: 
The site of inflammation
The pathogen or foreign body has molec-
ular patterns that are recognized by a variety of
cells present in the tissue. These cells, in turn,
release pro-inflammatory chemokines and cy-
tokines. These chemical factors activate the
neutrophils and the ECs to elicit an inflamma-
tory response. For example, lipopolysaccha-
rides can act as pathogen-associated molecular
patterns (PAMPs), which increase expression
of integrin CD18 and CD11b in neutrophils and
induce reactive oxygen species (ROS) produc-
tion. Certain bacterial lipoproteins, including
those from Treponema denticola, also can in-
duce ROS production by neutrophils and exo-
cytosis  of  specific  granules  [6].  Another
prominent example is the recruitment of neu-
trophils to the site of inflammation by My-
cobacterium  tuberculosis,  the  bacteria  that
causes tuberculosis. Originally recruited to kill
the bacteria, there is evidence suggesting that
activated neutrophils cause damage to the host
lung tissue and contribute to the development
of pathology [6,7].
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The EC layer responds to inflammatory
cues by differential expression of surface
proteins that abet the recruitment of neu-
trophils and other immune cells. ECs also
release nitric oxide (NO), cytokines, and
chemokines to act as signals that modulate
inflammation.
Neutrophils
Activated neutrophils release a variety
of factors, including proteases (i.e., matrix
metalloproteases, neutrophil elastase, colla-
genase), reactive oxygen species, cytokines,
and chemokines. Proteases, cytokines, and
chemokines aid in neutrophil recruitment
and migration to the site of inflammation,
and once there, reactive oxygen species pro-
mote  pathogen  death  and  phagocytosis.
Neutrophil and EC-derived factors during
inflammation constitute the majority of the
literature in this area of research. 
The extracellular matrix
An understudied area of research is the
effect of the ECM on inflammation. There
is increasing evidence suggesting that ma-
trix proteins such as collagen, laminin, fi-
bronectin, and fibrinogen play a crucial role
in neutrophil recruitment. For this reason,
matrix proteins should be included in exper-
imental models designed to understand in-
flammatory diseases. 
This review will focus on the role of the
ECM in inflammatory diseases, as relates to
modulation of neutrophil-EC interactions.  
The Extracellular Matrix and 
Neutrophil-Endothelial Interaction
The majority of the literature repre-
senting research of neutrophil-mediated in-
flammation revolves around elucidating the
protein expression profiles of activated neu-
trophils and ECs and examining the mech-
anisms by which inflammatory events are
regulated by changes in adhesion molecule
expression.  There  is  extensive  literature
covering many aspects of neutrophil-EC in-
teractions focused on the effects of ROS
during inflammation and varying surface re-
ceptor expression by both cell types [3,8].
The most commonly implicated receptors
are integrins, CD11b and CD18 on neu-
trophils and their ligands ICAM-1, VCAM-
1, E-selectin, L-selectin, and P-selectin on
ECs [3,4]. Many of these neutrophil inte-
grins are altered in their expression, as an
effect of neutrophil transmigration across
the endothelium. In fact, CD11b is doubled
in its expression, providing more adhesion
molecules available for binding ECM lig-
ands. Gonzalez et al. have demonstrated
changes in neutrophil adhesion, motility,
and velocity as an effect of altered integrin
expression post-transendothelial migration
[9]. The phenotypically altered neutrophils’
activity within the ECM is, therefore, sub-
stantially different from neutrophil response
in the vasculature.
Another important aspect of the neu-
trophil-EC interaction is the effect of the
ECM.  The  question  was  probably  first
raised in 1998 when Ketteritz et al. tested
and  confirmed  the  hypothesis  that  neu-
trophil-matrix interactions influence neu-
trophil  apoptosis  [10].  Luscinskas  et  al.
continued this work to demonstrate that the
interaction between fibrinogen (an ECM
protein) and the CD11b integrin interaction
was  primarily  responsible  for  signaling
events that prolonged the life of the neu-
trophil  [11].  Beyond  signaling  survival
events, others have demonstrated the im-
portance of matrix proteins in migratory
events, both within the vasculature and in
the extravascular space. Wang et al. have
shown that neutrophils prefer transmigrat-
ing through regions with low ECM protein
localization [12]. Other independent studies
have confirmed the presence of these “low
expression regions” that act as the prefer-
ential  sites  of  neutrophil  transmigration
through the endothelium [13,14]. The past
decade has seen multiple studies examining
the interaction between matrix proteins and
neutrophil activity [15-18]. In particular,
polymer-based hydrogels have been identi-
fied as ideal research models to study the
effect of matrix proteins. Specific bioactive
peptide sequences derived from ECM pro-
teins can be easily immobilized onto poly-
mer chains of (poly)ethylene glycol (PEG),
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works can be used to isolate the effects of
matrix proteins on neutrophils [19].
ECM proteins can affect activated neu-
trophils at multiple steps of the leukocyte
adhesion cascade. Matrix proteins can reg-
ulate neutrophil apoptosis through control
of tumor necrosis factor-alpha (TNF-α), in-
directly regulating local inflammation [10].
There is also evidence for ECM proteins
and activated ECs increasing the lifespan
of neutrophils [20]. Ginis et al. were able
to  demonstrate  protection  against  neu-
trophil apoptosis as a result of adhesion to
matrix proteins fibronectin and laminin and
activated EC-coated substrates [20]. More-
over, studies indicate that proteolysis plays
a role in neutrophil movement through the
basement membranes, an integral part of
the inflammation model as well [21].
Extracellular Matrix Proteins 
and Disease Models
Matrix proteins have been found to
have substantial roles in the pathogenesis
of an increasing number of inflammatory
disease models. Prominently, host-tissue
injury occurs as a neutrophil response to
signals from ECM proteins in the imme-
diate microenvironment. Activated neu-
trophils  can  release  a  host  of  matrix
modifying proteins, including neutrophil
elastase, myeloperoxidase, and defensins,
contributing to the formation of athero-
sclerotic plaques [22-24]. Tumorigenesis,
regulation of tumor growth, and tumor cell
invasiveness  can  also  be  modulated  by
neutrophil  contributions.  Because  neu-
trophils can be both anti- or pro-tumori-
genic, methods of regulating their tumor
cytotoxic abilities are currently being de-
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Figure 1. Neutrophil response to EcM proteins regulates their activity in multiple
disease states. a. In the arterial development and progression of atherosclerosis, the ac-
tivated neutrophil and inflamed EC produce and express proteins that contribute to the for-
mation of the lipid plaque. Accumulation of matrix proteins, including fibrin and collagen,
contribute to the immobilization and stabilization of the lipid plaque. Neutrophils and ECs
subsequently release proteases and oxidants that destabilize the architecture of the
plaque, inducing plaque rupture and immobilization. b. In the post-capillary venule of the
lung, neutrophil and EC activation can result in the production of oxidants that damage the
surrounding tissue matrix. As neutrophils enter into the remodeled matrix, they continue
the process of protease release and continue to remodel the microenvironment, facilitating
localized inflammation and irritation, symptomatic of COPD. c. Inflammation in the post-
capillary venule contributes to the progression of tumor metastasis. Microvascular EC are
activated by tumor-released chemokines to induce neutrophil adhesion and tissue infiltra-
tion. Neutrophils release oxidants and proteases that remodel the microenvironment, aid-
ing in tumor cell recruitment to pre-metastatic tissues. veloped [25,26]. Finally, chronic obstruc-
tive pulmonary disease (COPD) is yet an-
other  inflammation-related  disease  in
which neutrophil-released cytokines, elas-
tase, and oxygen radicals are essential to
the  pathogenesis  of  the  disease  and
thereby  targets  for  its  treatment  [27].
Thus, neutrophil recruitment, transmigra-
tion across the EC layer, and migration
through the ECM to reach the site of in-
flammation  is  key  to  multiple  disease
models [1,3,5,8,28].  
While neutrophil-EC interactions have
been investigated in various disease mod-
els, the role of matrix protein regulation of
neutrophil activity has been underappreci-
ated and may provide multiple therapeutic
opportunities for inflammation related dis-
orders including sepsis and arthritis [29-
32]. This review will examine the current
literature describing the effects of matrix
proteins on neutrophil-EC interaction and
its  relevance  to  three  different  disease
models: 1) atherosclerosis, 2) COPD, and
3) tumor growth and progression. We hope
to summarize the results so far and iden-
tify opportunities for further research. Fig-
ure 1 illustrates important neutrophil-ECM
interactions across these disease models.
dETAIlEd REvIEw OF ThE ROlE
OF NEuTROPhIl ANd ThE EcM IN
SPEcIFIc dISEASE MOdElS
Atherosclerosis
Our understanding of atherosclerosis as
a disease has evolved over the years. It is
characterized by the accumulation of fatty
substances that can build up to form plaques
along the inner walls of the arterial lumen.
The disease starts with fatty streaks on the
blood vessels that give rise to fibrous or
complex plaques. Plaque formation starts
with  the  transportation  and  retention  of
lipoproteins in the arterial wall. The lipopro-
teins get trapped in a mesh of fibrils and
fibers secreted by the arterial wall. The as-
sociation of these proteins with the ECM
forms the plaque, which can be oxidized by
neutrophil- and EC-secreted factors [33].
Not only are the plaques composed of fatty
lipids, but also platelets, foam cells, fibrino-
gen, and other ECM proteins. When these
plaques rupture, they cause thrombosis. Ath-
erosclerosis is a chronic inflammatory con-
dition that converts itself into a clinically
significant  disease  upon  the  initiation  of
plaque formation. In contrast to other in-
flammatory diseases, the observed inflam-
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Figure 2. Schematic representation of important regulatory molecules and events
during inflammation in atherosclerosis. a. Matrix proteins differentially regulate the acti-
vation of EC in response to changes in shear stress applied by blood flow. Fibronectin pro-
motes localized inflammation, while collagen and laminin inhibit flow-induced
atherosclerotic inflammation. b. LDL deposits become immobilized by collagen proteins to
form atherosclerotic plaques. Meanwhile, platelets, fibrin, and Defensins released by neu-
trophils contribute to the structural integrity of the developing plaque. c. Subsequently, cy-
tokine-activated neutrophils and ECs release oxidants and proteases that contribute to the
destabilization and rupture of lipid plaques. d. Ruptured plaque fracture into the blood
stream, entering the heart or brain to induce heart attack or stroke.mation and formation of lipid plaques in ath-
erosclerosis occurs within the structure of
the large vessel, rather than smaller post-
capillary  venule.  The  location  of  these
plaques would necessitate two important
features in the atherosclerotic inflammatory
model: First, as a disease that is established
in the vasculature, there is little contribution
from the extravascular ECM proteins typi-
cally associated with neutrophil inflamma-
tory activity in the tissue. Rather, matrix
protein found in the blood plasma (i.e., fib-
rin) contribute to the accumulation of coag-
ulated lipids, cells, and proteins that make
up the plaque [34]. Second, the accumula-
tion of platelets and blood matrix proteins
on the wall and throughout the core of the
plaque will contribute substantially to prop-
agating the pro-inflammatory neutrophil re-
sponse upon encountering the plaque. Blood
flow and the structure of the plaque itself
provide an opportunity for direct contact of
neutrophils with the fibrotic plaque, allow-
ing  the  neutrophil  to  promote  continued
plaque growth and ultimately destabiliza-
tion. Assessing the role of neutrophils in the
progression of atherosclerosis and destabi-
lization of the atherosclerotic plaque could
lead to identification of cellular and protein
targets for therapeutic applications.
The Role of Neutrophils in Atherosclerosis
Neutrophils play a distinct role in the for-
mation of atherosclerotic plaques and athero-
sclerotic progression. Through production and
degradation of plaque protein components,
neutrophils are key to the development of ath-
erosclerosis and resulting ischemic reperfu-
sion injury, effectively resulting in myocardial
infarction and stroke (Figure 2). In the devel-
opment of atherosclerotic plaques, activated
neutrophils contribute early on through the re-
lease of the protein Defensin at the site of EC
damage [23,35]. Defensin forms stable com-
plexes with low density lipids that effectively
results in further immobilization of the com-
plexes. These complexes bind blood plasma
proteins, leading to lipid accumulation and
plaque formation [36].
Atherosclerotic  human  arteries  with
plaques  express  matrix  metalloproteases
(MMPs), which are a family of homologus
zinc-dependent endopeptidases enzymes ca-
pable of inducing plaque rupture by lysis of
ECM proteins [37,38,39]. While atheroscle-
rosis has been associated with vascular re-
modeling since the 1990s, only recently has
a direct correlation been made between high
neutrophil numbers, high MMP content, and
destabilization of plaques [40]. However,
the role of neutrophil-released MMPs in ath-
erosclerosis  is  complex.  For  example,
MMP-9 released by neutrophils during ath-
erosclerosis  is  regulated  by  neutrophil
gelatinase-associated lipocalin [41]. Gelati-
nase-associated lipocalin is a high-molecular
weight glycoprotein, which acts as a scav-
enger of bacterial products, thus modulating
the inflammatory environment [41]. The dif-
ferential roles of distinct neutrophil-released
MMPs in remodeling and degradation re-
main unresolved. Generally, MMPS degrade
the proteins that make up the plaque, reduc-
ing its stability under flow within the vessel,
allowing it to disassociate from the vessel
wall [42].
While MMPs have been associated with
plaque destabilization, the effects of oxi-
dants on degradation of the ECM is a topic
of increasing interest. Peroxynitrite, formed
in the reaction between endothelial-released
nitric oxide and neutrophil-released super-
oxide ions, has been shown to induce major
structural and functional changes to the he-
parin sulfate proteoglycan perlecan, which
leads to weakening of the ECM, thus, in-
creasing the risk for heart attack and stroke
[43]. Wang et al. have shown that peroxyni-
trite can regulate the activity of MMPs, sug-
gesting that ROS may contribute to ECM
degradation through MMP activation [44].
Peroxynitrite  can  oxidize  tropoelastin,  a
monomer of elastin, and has been shown to
interfere with matrix elastin fiber assembly
and tropoelastin-cell binding, resulting in
progression of atherosclerosis [45]. Addi-
tionally, as previously mentioned, ROS are
intricately involved in the regulation of the
interaction of neutrophils and EC adhesion
molecules, with evidence suggesting both
pro- and anti-inflammatory roles in the lit-
erature  [46-49].  Another  common  neu-
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tase, which can degrade elastin, damaging
the matrix. On the other hand, neutrophil-
mediated damage can be contained by the
production  of  α1-antitrypsin,  an  anti-in-
flammatory agent produced during exercise.
It is thought that regular exercise can in-
crease α1-antitrypsin levels, effectively con-
taining the progression of atherosclerosis
[50]. 
The Role of Matrix Proteins in 
Atherosclerosis
Recent reports indicate that matrix pro-
teins may modulate the development and
progression of atherosclerosis [48]. This is
due to ECM protein-mediated modification
or stabilization of lipids deposited on the ar-
terial wall, as well as ECM-mediated regu-
lation  of  cellular  contributors  to  plaque
formation (Figure 2). Atherosclerosis can be
induced in rats by feeding them diets with
high low density lipid (LDL) content and is
modified by extracellular components. In
1994, Nievelstein-Post et al. showed that the
LDLs can associate with proteoglycan fila-
ments, joining collagen fibers, which subse-
quently modify the structure of the lipid
[49]. Collagen is of particular interest when
it comes to atherosclerosis, because collagen
content increases with plaque formation and
can make up to 60 percent of the protein
content of plaques [51,52]. Again, cellular
interaction with collagen is integral to adhe-
sion and transmigration of neutrophils, sug-
gesting that it may play a role in neutrophil
response to the collagen abundant plaque.
Collagen content of the ECM can be de-
graded by neutrophil-released factors, in-
cluding MMP-8 [52,53]. Multiple isotypes
of this protein also bind to LDL and con-
tribute  to  the  structural  integrity  of  the
plaque [53,54]. Recent findings have led to
the hypothesis that the behavior of vascular
cells is dictated, in part, by the ECM [42].
Specifically, many matrix proteins appear to
have differentially protective effects on EC,
while others are pro-inflammatory. Induc-
tion of atherosclerosis by disturbed blood
flow, for example, can be modified by ma-
trix proteins. When ECs are plated on fi-
bronectin or fibrinogen, they activate the nu-
clear factor kappa B (NF-κB) pathway in re-
sponse to flow, but not when they are plated
on collagen or laminin. Ligation of specific
integrins on collagen prevents flow-induced
NF-κB activation [48]. NF-κB is a protein
that acts as a transcription factor and hence
regulates the expression of multiple proteins
with varied effects, including inflammation.
Activation of NF-κB upregulates expres-
sions of genes for E-selectin, ICAM-1, and
VCAM-1, all of which are modulators of
neutrophil-endothelial interactions and are
also subject to alteration by ROS [46-48].
Therapeutic Opportunities
As  our  understanding  of  various  in-
flammatory contributors to atherosclerosis
is growing, more and more therapeutic tar-
gets are revealing themselves. To inhibit the
initial development of plaques, defensin is a
plausible target. Modification of MMPs is
another route currently proposed as a thera-
peutic approach [42]. Most recently, bio-
medical engineers in the field of vascular
graft development have created functional
blood vessels from synthetic matrices, in
which immunological cells are known to
contribute to the formation of the complex
vascular  structure.  Roh  et  al.  utilized
biodegradable scaffolds composed of a syn-
thetic  (poly)glycolic  acid  mesh  and  a
copolymer  sealant  solution  to  seed  bone
marrow mononuclear cells prior to implan-
tation into the mouse inferior vena cava.
After 24 weeks in vivo, the synthetic poly-
mer base had transformed into a functional
blood vessel, resembling native mouse ves-
sel with layers of endothelial cells, smooth
muscle cells, and collagen fibrils [55]. This
work is a clear advancement in the develop-
ment of vascular biology, creating a model
by which the contribution of immunological
cells can be elucidated in development of
healthy vasculature, but also in the develop-
ment of aberrant immunological responses,
including atherosclerosis.  
Additionally, many of the molecules and
proteins that alter the ECM can be regulated
by the ECM itself. With regard to neutrophils,
the key may be to modulate the secretion of
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portant proteins (i.e., defensins, neutrophil
elastase) to promote the stability of athero-
sclerotic plaques. The matrix composition of
the  plaque  itself  dictates  many  of  the
processes that regulate neutrophil behavior.
For example, collagen and laminin can pre-
vent NF-κB activation to lower peroxynitrite
levels, subsequently general inflammation in
the local area [48]. Strategies to increase ex-
pression of collagen or laminin and decrease
expression of fibronectin by the EC layer lin-
ing the plaques might prove efficient in de-
creasing neutrophil attachment to plaques.
Another avenue of ongoing research is the
development  of  drugs  targeted  to  inhibit
MMPs localized to arterial plaques, thus in-
hibiting plaque rupture. For example, MMP-
1, MMP-13, and MMP-8 are three specific
MMPs  that  are  overexpressed  in  human
arethroma [53]. It will be beneficial to de-
velop anti-inflammatory drugs that could be
coupled to antibodies specific to one or more
of the mentioned MMPs. Silencing MMP-1
or MMP-8 might increase the stability of the
atherosclerotic plaques and prevent rupture.  
Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease
is a high-risk lung injury characterized by
deterioration of small airways, emphysema,
and, in some cases, bronchitis. It is often as-
sociated with inflammation and structural
remodeling [27]. Some of the key concepts
regarding the role of neutrophils in COPD,
the effect of matrix proteins, and therapeutic
opportunities have been summarized below.
The Role of Neutrophils in COPD
During the inflammatory response, neu-
trophils release oxygen radicals, elastase,
and  cytokines,  which  contribute  to  the
pathogenesis of COPD [27]. To reach the
site of inflammation, neutrophils transmi-
grate through the endothelial layer of small,
post-capillary  vessels.  To  initiate  this
process, neutrophils become activated by
chemoattractants, migrate toward increasing
concentrations of the chemoattractant and
respond by upregulating surface receptors
that attach to leukocyte adhesion molecules,
including platelet endothelial cell adhesion
molecule  (PECAM-1)  and  ICAM-1  ex-
pressed by ECs (Figure 3) [3,27]. ICAM-1
and PECAM-1 serve as adhesion molecules,
providing an anchor for firm neutrophil ad-
hesion to and subsequent migration across
the EC. In order to access the extravascular
matrix, neutrophils have been observed to
migrate directly through the EC cell body,
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Figure 3. Schematic representation of important regulatory molecules and events
during inflammation in cOPd. a. Adhesion molecules, including PECAM, regulate neu-
trophil attachment to EC, encouraging neutrophil entry into the ECM. b. Neutrophils are
recruited by matrix proteins, including collagen and mindin, to infiltrate the extravascular
space. c. Attachment to matrix protein Laminin induces neutrophil elastase release. d. Ac-
tivated neutrophils and EC continue to release both pro- (ROS) and anti-inflammatory
(NO) factors. These contribute to the remodeling of the ECM and recruitment of additional
leukocytes, all leading to emphysema symptomatic of COPD. (Lung image adaped with
permission from http://www.buzzle.com/articles/restrictive-lung-disease.html.) though their preferred course of migration
occurs at bi-and tri-cellular junctions be-
tween ECs. Besides an upregulation of ad-
hesion molecules, the site of transmigration
is also marked by low expression of matrix
proteins (i.e., laminin) [12]. Soon after mi-
grating across the EC layer, neutrophils in-
teract with matrix proteins through β1 and
β3 integrins found on the surface of the neu-
trophil. Matrix metalloproteases (including
MMP-8, MMP-9) and neutrophil elastase
are released by neutrophils to play a key role
in degrading the ECM and provide physical
pathways for matrix migration of more neu-
trophils during airway inflammation [56-
60]. 
In COPD, endothelial cell mediated NO
production is impaired, and ICAM-1 ex-
pression is up-regulated [61,62]. NO levels
are increased in the exhaled breath of COPD
patients  during  exacerbations  in  COPD
symptoms [63]. NO combines with super-
oxide anion, or ROS, to form peroxynitrite
[64]. Due to the combination of elevated NO
and ROS release, patients with COPD also
have higher levels of peroxynitrite in the
breath condensate and sputum. The ability
of endogenous antioxidants present in the
lungs to inhibit the activity of peroxynitrite
is also reduced, increasing the damage in-
duced by peroxynitrite and its components
[65].
In general, the role of NO and perox-
ynitrite in inflammation has been a matter of
debate [44]. Therefore, it is relevant to cite
some conflicting reports on how peroxyni-
trite  affects  neutrophil-EC  interaction
[46,47,66,67]. There have been studies indi-
cating that peroxynitrite decreases adhesion
of neutrophils to the endothelial surface and
may contribute to decreasing the functional
interaction  between  the  two  cell  types
[47,66]. On the contrary, other groups have
confirmed that peroxynitrite increases adhe-
sion molecule expression and helps to in-
crease  the  strength  of  the  neutrophil-EC
interaction [46,67,68]. Since peroxynitrite
levels have been shown to be elevated in the
sputum and exhaled air of COPD patients,
indicating that the lungs are experiencing
more peroxynitrite generation, it is impor-
tant to understand the role of these species in
pulmonary diseases. Again, the role of per-
oxynitrite, either upstream or downstream of
cell-cell and cell-matrix interactions, will be
key  to  the  development  of  therapeutics
against extensive tissue damage in COPD.
Identification of regulatory proteins govern-
ing inflammatory events may also shed light
on these interactions.
The Role of Matrix Proteins in COPD
In contrast to the large vessels affected
by atherosclerosis, the lung vasculature is
closely associated with an epithelial cell
layer. The small blood vessels associated
within the alveoli lie in close proximity to
the epithelium of lung tissue, sharing a base-
ment membrane and ECM (Figure 3). Stud-
ies have confirmed that these matrix proteins
are  active  contributors  to  the  process  of
transmigration through the endothelium of
the  lung  microvasculature.  Collagen  and
collagen-like polypeptides have been shown
to serve as chemoattractants for neutrophils,
contributing  to  enhanced  inflammation
[69,70]. Weathington et al. identified acety-
lated PRO-GLY-PRO (ac-PGP), a peptide
segment  derived  from  collagen,  to  have
chemotactic activity, recruiting neutrophils
for an inflammatory response both in vitro
and in vivo [58]. It has been suggested that
ac-PGP  is  a  collagen-derived  molecular
mimic of interleukin-8 (IL-8), which acti-
vates the neutrophils and causes an upregu-
lation  of  inflammation,  a  potential
contributor in COPD. The cleavage of ECM
proteins that leads to the formation of ac-
PGP is mediated by metalloproteases.  This
fits well into the currently described role of
neutrophils,  shown  to  release  neutrophil
elastase, which contributes to activation of
MMP-8, resulting in degradation of matrix
collagen [56,63]. 
Besides collagen fragments, matrix pro-
teins fibronectin, laminin, and elastin ex-
pressed  in  the  lung  have  been  shown  to
influence neutrophil-EC interactions. Par-
ticularly, MMP-12-mediated degradation of
elastin could result in chemotactic elastin
fragments that recruit inflammatory cells,
aiding in progression of emphysema [71].
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the neutrophil integrin and has been shown
to be essential for neutrophil recruitment to
the site of inflammation [72]. Laminin, a
fairly abundant matrix protein, has also been
shown to induce neutrophil MMP release
and chemotaxis specifically through inter-
actions with the α5 domain [73]. Thus, the
complex modulatory effect exerted by the
matrix proteins, particularly collagen and
laminin, can regulate the level of neutrophil-
mediated inflammation in the lung.
Therapeutic Opportunities
In summary, chronic obstructive pul-
monary disease is widespread, with millions
of patients being diagnosed every year. It
has emerged to be the third leading cause of
death in the United States, 12 years earlier
than predicted [74]. Investigation into the ef-
fect of matrix proteins, including collagen,
laminin,  mindin,  and  their  bioactive  do-
mains will be valuable areas of research. For
example, development of drugs to shield
mindin  or  decrease  its  expression  in  the
basement membrane may contain neutrophil
infiltration and neutrophil-induced inflam-
mation in COPD. Drugs to block specific
MMP cleavage sites of abundant matrix pro-
teins, including collagen, could be a prom-
ising alternative. Elucidation of individual
roles for inflammatory modulators, includ-
ing elevated peroxynitrite levels in lungs of
COPD patients, regulation of integrin re-
ceptor molecules, and other signaling fac-
tors,  will  provide  a  better  insight  to  the
causes and therapeutics for COPD.
Revelations of matrix protein compo-
nents with protective effects against inflam-
mation  will  be  useful  in  creation  of
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Figure 4. Schematic representation of important regulatory molecules and events
during inflammation in tumor growth and progression. a. Tumor-secreted GMCSF
supports neutrophil recruitment to the tumor site. Simultaneously, matrix proteins, collagen
and laminin, are deposited in the microenvironment immediately surrounding the tumor. b.
Reactive oxygen species released by invading neutrophils is initially cytotoxic to tumor
cells, and the release neutrophil proteases contribute to tumor matrix remodeling. c. Neu-
trophils, conditioned by VEGF and bFGF (growth factors abundant during tumor angiogen-
esis), continue to release factors that remodel the matrix and support tumor cell migration
into the blood stream. Meanwhile, matrix proteins (i.e., matricellular glycoprotein SPARC)
themselves contribute to regulation of tumor growth. d. Tumor-secreted chemokines pro-
mote preparatory neutrophil-mediated inflammation in a distant pre-metastatic tissue
(lung), allowing for EC activation and matrix remodeling, for subsequent tumor cell inva-
sion and seeding.  cell-therapeutic  strategies.  Inducing  in-
creased protective matrix proteins produc-
tion by ECs or epithelial cells lining the
basement  membrane  could  significantly
alter the lung microenvironment. Biomed-
ical engineers currently are taking advantage
of both synthetic and natural matrices to in-
vestigate the innate properties of the lung
matrix components. Most notably, Miller et
al. have demonstrated the use of natural ma-
trix proteins for use in adhesion molecule
mediated tissue development. In this work,
naturally  derived  polymers  and  acellular
whole tissue matrices are used as the basis
for  tissue-engineered  bronchioles  of  the
lung. Petersen et al. have produced a human
bronchiole model composed of lung fibrob-
lasts embedded in a collagen matrix sur-
rounded by airway smooth muscle cells and
bronchial  epithelial  cells  [75-76].  This
model can be used to examine airway re-
modeling events associated with chronic res-
piratory disease, including COPD. This is
but one of the many examples of natural and
synthetic ECM mimetics currently used and
under development for investigation of in-
flammation-mediated diseases. Neutrophil
elastase  is  another  major  target  to  treat
COPD. The major challenge in targeting
neutrophil elastase has been the simultane-
ous accomplishment of potency and selec-
tivity  of  the  drug  [60].  Drugs  to  locally
inhibit neutrophil-released factors that de-
grade the matrix (i.e., MMP-9 and MMP-8)
are also attractive options for further re-
search. 
Tumor Growth and Progression
The processes of tumor progression and
metastasis bear numerous similarities when
compared to the process of neutrophil infil-
tration into tissue during inflammation. Both
tumor  infiltration  into  blood  vessels  and
neutrophil infiltration into the matrix in-
volves crossing cell and protein barriers.
Both processes necessitate release of pro-
teases, which degrade the matrix, to make
way  for  infiltration.  Neutrophil-released
neutrophil elastase, MMPs, and cytokines
matrix damage can contribute to tumor in-
vasiveness and metastasis [26]. Thus, tumor
progression  and  growth  of  many  cancer
types have been related to inflammation me-
diated factors. In addition, inflammation has
been  identified  as  a  precursory  event  to
seeding of metastatic tumor cells in unaf-
fected tissue (Figure 4). Tumor cell transmi-
gration, occurring as tumors cells move into
the blood vessels, has been shown to be pro-
moted by neutrophils [77]. The role of neu-
trophil-released inflammatory molecules as
a pro-tumorigenic factor and the effect of
matrix proteins in the development of cancer
are new avenues of research for cancer treat-
ment and therapy.
The Role of Neutrophils in 
Tumor Progression
Neutrophils are cytotoxic to tumor cells
through the release of large amounts of neu-
trophil elastase and ROS. However, neu-
trophils can contribute tumor progression by
preparing the microenvironment for tumor
invasion. Granulocyte-macrophage colony
stimulating  factor  (GM-CSF),  present  in
tumor growth medium, leads to increased
expression of neutrophil CD11 and CD18,
enabling neutrophil-induced tumor transmi-
gration into the extravascular space [77]. In-
flammation in the pre-metastic tissue space
is considered an indicator of a pro-metasta-
tic  environment.  Likewise,  tumors  have
been shown to recruit neutrophils from the
blood into the extravascular space through
secretion of chemokines by both direct re-
lease of interleukins and signaling produc-
tion  of  excess  IL-8  from  vascular  cells
[78,79]. Neutrophils bind to tumor-secreted
chemoattractants, become activated, adhere
to the vascular endothelium, and transmi-
grate  through  the  EC  layer  and  into  the
ECM. This process is accompanied by neu-
trophil release of MMPs and ROS, remod-
eling the ECM (Figure 4) [78]. Figure 4 uses
metastasis of breast cancer to the lung as an
example to summarize the important events
and regulatory molecules in tumor develop-
ment, which are common to many cancer
types. 
Neutrophils can facilitate tumor inva-
siveness and growth by damaging the vas-
culature  through  release  of  multiple
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through the release of cytokines, or by bind-
ing directly to the tumor cells to facilitate
tumor cell-transmigration (Figure 4) [77,80].
Evidence of these functions has been sup-
ported by elevated numbers of neutrophils
found in several tumors, including adeno-
carcinoma, melanoma, and myxofibrosar-
coma  [81].  Among  the  various  factors
released by neutrophils are neutrophil elas-
tase, MMP-9, MMP-8, and cytokines. Neu-
trophil elastase can effect a broad range of
substrates, including many of the ECM pro-
teins [82]. Neutrophil elastase also acts in a
dose dependent manner, inducing tumor cell
proliferation at low concentrations and cell
death at very high concentrations. Houghton
et al. have summarized the effects of neu-
trophil  elastase,  MMP-8,  and  MMP-9  in
tumor  growth  very  well  [26].  MMP-8,
MMP-2, and MMP-9 are all released by
neutrophils during inflammation and help
degrade  matrix  components  for  efficient
neutrophil infiltration into tissue. These pro-
teases also have been found to contribute to
tumor invasiveness by remodeling the tissue
matrix  [83-85]. Additionally,  neutrophils
and tumor cells can act together to enhance
tumor cell recruitment. GM-CSF released by
tumor cells serves as a chemoattractant and
stimulant for neutrophils and their release of
Oncostatin M. Neutrophil-secreted Oncas-
tatin M promotes tumor progression by en-
hancing angiogenesis and metastasis. In this
manner, both metastatic tumor cells and neu-
trophils work together to increase tumor pro-
gression and invasiveness. Thus, inhibiting
Oncostatin M and GM-CSF may be poten-
tial avenues to reduce tumor growth and pro-
gression [86].
Neutrophils are found in elevated num-
bers in tumors, and hence, ROS concentra-
tions  in  tumors  and  their  immediate
microenvironment are also high. Neutrophils
increase the NO content of murine tumor
models and have been shown to be muta-
genic, contributing to the burden of genetic
abnormalities  associated  with  tumor  pro-
gression [87]. Altered iNOS and NO pro-
duction  also  have  been  observed  in  oral
cavity cancer, leading to speculations that
these molecules might regulate tumor-neu-
trophil relationships [88]. Peroxynitrite re-
sults  in  nitration  of  various  molecular
species, which may have relevance in cancer
progression. Peroxynitrite has been shown to
produce nitrated genistein, a molecule that
alters the tumor-inflammatory environment
[89]; however, further research is required to
elucidate the effects of altered genistein on
tumor invasiveness. Nevertheless, reports in-
dicate  that  ROS  and  their  intermediates
might lead to decreased melanoma cell via-
bility [90]. Again, the role of ROS is con-
centration dependent, having been shown to
be support tumor progression at modest con-
centrations and cytotoxic to tumor cells and,
hence, anti-tumorigenic at high concentra-
tions [26,91]. 
The Role of Matrix Proteins 
in Tumor Progression
The ECM has a variety of proteins and
other structural components that can be ex-
ploited by neoplastic cells to create a tu-
morigenic  environment.  Matrix  proteins
including  syndecan-1,  collagen-IV,  and
laminin  have  been  shown  to  be  overex-
pressed in tumors and have been used as
markers for tumor detection [92]. Vascular
endothelial growth factor (VEGF) and basic
fibroblast growth factor (bFGF) are ECM-
bound proteins with tumorigenic properties,
specifically triggering angiogenesis in the
tumorigenic environment. Both VEGF and
bFGF stimulate EC production of multiple
proteolytic enzymes that assist in EC migra-
tion and proliferation (Figure 4). Many stud-
ies have demonstrated that upregulation of
these factors effectively leads to tumor for-
mation [93,94]. 
Besides the aforementioned biochemi-
cal signals, there is also evidence that the
provisional ECM and its component pro-
teins,  including  fibrinogen,  contribute  to
regulating neutrophil recruitment and tumor
metastasis (Figure 4) [95-97]. Multiple types
of tumors have been found to contain fib-
rinogen, and fibrinogen degradation prod-
ucts have been shown to have angiogenic
and  chemotactic  properties  [95].  SPARC
(secreted protein acidic and rich in cysteine)
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Table 1. current anti-inflammatory therapeutic targets.
disease/
condition
COPD
Atherosclerosis
Tumor growth
and progression
Neutrophil-
released factors
1. MMP-8
2. Nitric Oxide
3. Peroxynitrite
4. Neutrophil 
Elastase
1. MMP-8, MMP-9
2. Peroxynitrite
3. Defensins
1. MMP-2, MMP-8,
MMP-9
2. Oncastatin M
3. Neutrophil 
Elastase
4. Peroxynitrite
5. Nitric Oxide
Matrix 
proteins 
1.Collagen
2.Laminin
1.Fibrinogen
2.Collagen
3.Laminin
1.Collagen 
2. Laminin
3. SPARC
4. VEGF
Targeted anti-inflammatory 
therapeutic approaches
1. Corticosteroids : Non-specific
treatment for exacerbations act
against IL-8, TNF-α, MMPs [99]
2. ICS/LABA – Corticosteroid + β2
Antagonist – increases translocation
of glucocorticoid from cell cytosol to
the nucleus and hence anti-inflam-
matory effects [99,100]
3. Antagonists to Integrin α4β1, se-
lectins, granulocyte adhesion –
aimed at decreasing interaction be-
tween leukocytes and ECs [99]
(Clinical Trials)
4. Adenosine A2a receptor Agonists:
Decreases neutrophil-EC adhesion
and release of ROS [99] (Clinical
Trial)
5. Phosphodiesterase -4 inhibitors:
Increase cAMP concentrations in
neutrophils, T-cells, leads to anti-in-
flammatory  effects [101-103]
1. Statins: Decrease VCAM, ICAM
on ECs, inhibit MMPs, lowers LDL
[104,105]
2. Phospholipase inhibitors: Lowers
LDL levels and decreases recruit-
ment of inflammatory cells to
plaques [104]
3. TNF-α Blockade: inhibits expres-
sion of TNFα, IL-8, IL-6, MMP-1,
MMP-3 [105]
4. Mutant MCP-1 gene transfection -
Targeting MCP-1, which is involved
in developing lesions and inflamma-
tion [106] (Animal studies)
1. NSAIDS: Non-steroid anti-inflam-
matory drugs and reduce inflamma-
tion. Shown to reduce cancer
occurrence in a variety of cancers
[107,108]
2. Specific COX-2 inhibitors: re-
duces side effects when given in
combination with NSAIDs [108]
3. Corticosteroids: reduced side-ef-
fects of chemotherapy and also has
anti-inflammation and anti-cancer
properties [109]is a glycoprotein protein found in the ECM
and  has  been  shown  to  have  anti-tumor
properties. In xenograft tumors, SPARC acts
to ablate VEGF, reducing the formation of
vasculature throughout the tumor. However,
the role of SPARC as a tumor inhibitor is
controversial. While SPARC expression has
been identified as a marker of aggressive tu-
mors, it has also been shown to have anti-
angiogenic properties [94,98].
Therapeutic opportunities
Tumor  growth  and  progression  are
complex processes involving a multitude of
factors. Neutrophil transmigration through
the endothelial layer (which is influenced
by the  ECM) and the ECM itself are both
factors that can contribute to the invasive-
ness of tumor cells. One consistent aspect
of recent studies is that many of the effects
of  inflammatory  molecules  involved  in
tumor progression are concentration de-
pendent [26,91]. This information suggests
that individual molecules may have dual
roles with respect to tumor progression. In
general, high concentrations of inflamma-
tory molecules have pro-host effects, while
low or modest concentrations have pro-
tumor effects. Another pattern observed in
the literature is that activated neutrophils
create a positive-feedback loop. ECM pro-
teins can regulate activation of neutrophils
and abet neutrophil transmigration. Devel-
oping strategies to control the release of in-
flammatory molecules by neutrophils or
strategies to interrupt the communication
between neutrophils and tumors cells may
be key to containing tumor metastasis. In
all, identifying matrix proteins and their
concentration ranges, which may prevent
excessive  neutrophil  transmigration  dic-
tated by tumor-induced chemoattractants,
may be a method to curb tumor progres-
sion. The role of ROS is also to be studied
in light of the matrix composition and how
that affects tumor cell viability. To reiter-
ate, one has to be mindful while studying
inflammatory contributors to tumor growth
and development, as they are only a singu-
lar subset of the many factors playing a role
in tumorigenesis and tumor progression.
Table 1 summarizes the key molecular
species associated with neutrophils, ECs and
the ECM that are central to the disease mod-
els discussed and possible therapeutic tar-
gets. 
chAllENgES FOR BIOMEdIcAl
ENgINEERINg
In conclusion, there is increasing evi-
dence that the ECM should be exploited as a
therapeutic target against inflammatory dis-
eases. This field of study warrants more
focus to elucidate the effect of the abundant
matrix proteins (collagen, laminin, fibrino-
gen, and fibronectin) on neutrophil recruit-
ment and regulation of neutrophil-released
factors.  Neutrophil-released  factors  ROS
and peroxynitrite remain among the least un-
derstood signals in disease models.
The challenge ahead in neutrophil-medi-
ated inflammation research is two-fold. First,
it is important to characterize the concentra-
tion dependent roles of the neutrophil and
EC-derived factors during inflammation for
specific disease models. It would then be rel-
evant to explore the options to deliver drugs
specifically to inhibit the pro-inflammatory
signals or to enhance the effect of protective
or anti-inflammatory signals. It also would be
beneficial to generate smart materials that can
sense the concentrations of these factors in
the microenvironment and release anti-in-
flammatory drugs accordingly. Second, it is
imperative to identify matrix proteins that in-
herently reduce inflammation. These matrix
proteins could prove to be ideal for control-
ling inflammation in disease models. Inves-
tigating  ways  of  increasing  the  specific
“protective matrix protein” content of the
provisional matrix in diseased tissues would
be  worthwhile.  Protective  protein  matrix
mimetics are being explored as cell-directed
therapeutic devices. Further exploration of
the molecular pathways responsible for pro-
and anti-inflammatory effects of specific pro-
teins and ways to manipulate these effects in
vivo will lead to useful therapeutics for in-
flammatory diseases. 
We  also  recommend  some  caution
while considering these strategies. Different
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compositions and, subsequently, support dis-
tinct cellular behavior. This matrix variabil-
ity  could  pose  challenges  regarding
molecular targets being both disease-spe-
cific and tissue-specific. Another important
consideration is that the ultimate aim is not
to completely inhibit pro-inflammatory sig-
nals but reduce them to normal levels in dis-
eased tissues. A corollary to the above is that
treatment for inflammatory diseases should
be specifically targeted, since systemic ef-
fects can backfire by damaging the immune
system. More specifically, complete ablation
of inflammation could lead to devastating
infection. Last, other cell types including
macrophages, mast cells, and monocytes are
also involved during inflammation and the
role of these cells, and their signaling fac-
tors should be taken into account for further
therapeutic opportunities. 
The strategies proposed can be applied to
multiple disease models. Here we have outlined
only three of many diseases and disorders in
which neutrophil function can be controlled by
various  ECM  proteins.  Therapeutic  targets
based on matrix proteins have the potential to
target a wide variety of disease ranging from
simple allergies to deadly cancers.
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